FleurirABX has an executive team experienced in the management, commercialization, compliance, and financing of complex organizations.
Steven Volla, Chairman and Chief Executive Officer: Steve has over 35 yrs leading both public & private healthcare companies including American Health Management, Universal Health Services, and as a partner at MTS Health Partners. He was named Entrepreneur of the Year by Ernst & Young for turnaround of American Health Management. Steve holds an M.P.H. from University of California Los Angeles.
John L. Pace, Vice Chairman and Chief Scientific Officer: Dr. Pace is a distinguished senior scientist with 25 years of anti-infectives research experience. Dr. Pace is a named co-inventor on 20 U.S. patents including the MRSA antibacterial Vibativ. Dr. Pace has held leadership positions with both leading pharmaceutical and successful start-up drug-development companies including Stiefel-Glaxosmithkline, Novexel (acquired by AstraZeneca), Protez (acquired by Novartis), Theravance, Antex Biologics and Hoffmann-LaRoche. Dr. Pace earned a Ph.D. in Food Science from the University of Maryland.
Regina Reale, Chief Financial Officer: Ms. Reale has over 14 years of corporate finance experience with start-ups including as SVP of Corporate Development of Comprehensive Neuroscience and VP of private equity investments as GE Capital. She holds an M.B.A. Columbia Business School and B.S. in Accounting from St. John’s University.
Dr. Susan Gardlik, Chief Operating Officer: Dr. Gardlik has 24 years pharmaceutical experience at GlaxoSmithKline, specializing in portfolio and project management. As VP of Drug Discovery Portfolio Management, she managed a global team providing strategic and operational portfolio management for 35+ units with a portfolio of nearly 300 projects. She earned a Ph.D. in Biochemistry from Duke University.